Skip to main content
Premium Trial:

Request an Annual Quote

Gentronix, Altogen Biosystems, Guava Technologies, Velocity11, Invitrogen, Thermo Fisher Scientific

Gentronix has launched its new genotoxic metabolite-detection assay, the GreenScreen HC, the company announced this week.
The assay is now available with an S9 protocol to detect genotoxic metabolites, the company said. The manufacturer also said that the utility of GreenScreen HC has been extended to detect pro-genotoxins, in addition to common mechanistic classes of genotoxins, including mutagens, clastogens, aneugens, and topoisomerase and polymerase inhibitors.
Using a standardized 96-well microplate format, the test compound and patented green fluorescent protein reporter cells are combined with 1 percent S9 for a 3-hour exposure period. After exposure, cells are washed to remove the S9 and test compound and then allowed an additional 45-hour recovery incubation. Cell viability and GFP fluorescence data are assessed using flow cytometry, and software generates quantitative results and a graphical output.
According to Gentronix, GreenScreen HC can correctly identify non-carcinogenic compounds known to give misleading positive results in other in vitro genotoxicity assays.

Altogen Biosystems has launched a new contract research servicesdivision, the company announced this week.
The division, Altogen Custom Services generates stable cell lines by transforming the cell line of choice to stably express the vector or gene of interest. Optional cloning and shRNA expression services are available. The service turnaround time is typically three to four weeks, the company said.
Altogen’s laboratory research services include: transfection services (transient and stable); assay development and library screening; cloning and plasmid vector construction; generation of stable cell lines; siRNA design, synthesis, and validation; gene targeting (mRNA knockdown, shRNA overexpression); and custom services.

Guava Technologies this week announced the availability of its new RapidQuant IgG assays for the quantification of mouse and human antibodies. 
Used in combination with the Guava Express, Guava ViaCount, and other Guava assays, the new RapidQuant IgG assays provide antibody characterization on a single cellular analysis platform — the Guava EasyCyte Plus system.
The no-wash, microplate-based RapidQuant assays are bead-based and rely on fluorescence detection for the quantitative measurements. Standard curves are automatically produced by the software interface, removing the need for calculations performed by the user during analysis. The fluorescent intensity is proportional to the concentrations of antibody captured on the beads.
RapidQuant assays have been tested with human and mouse antibodies of all IgG subtypes and in many types of hybridoma media, the manufacturer said. RapidQuant kits are specific for IgG and are not hindered by the presence of fetal bovine serum or IgM in the media.
The RapidQuant Assay can be used to determine absolute concentrations of antibody present in cell culture medium or in purified preparations by comparison to a standard curve. Results from this assay can also be combined with results from the Guava Express assay to determine relative antibody affinities.

Velocity11 this week announced the launch of its Automated Microplate Spin-down workstation that enables batches of microplates to be spun down in parallel. 
Integrating the Velocity11 BenchCel microplate handling system and VSpin Access 2 automated microplate centrifuge, the new workstation can handle up to 320 microplates. A software interface allows users to specify the centrifugation settings.

Invitrogen has launched two new vectors for RNAi research, the company announced this week: the BLOCK-iT HiPerform Lentiviral PolII miR RNAi expression system with emerald green fluorescent protein, and the BLOCK-iT Inducible PolII miR RNAi Expression System.
The HiPerform with emGFP offers the ability to deliver to nondividing, primary, and hard-to-transfect cells with lentiviral technology coupled to multi-site technology for promoter flexibility, making it appropriate for applications such as in vivo RNAi. The new vector contains an mRNA stabilizing sequence (WPRE) and a nuclear import sequence (cPPT), which the company said generates up to five-fold higher virus titers and emGFP expression than previous versions.
The Block-iT Inducible system uses a tetracycline-inducible promoter that allows researchers to control miR RNAi expression so that even genes that are essential to the function of a cell may be knocked down, according to the manufacturer.

Allele Biotech has released a new fluorescent protein, mWasabi, a monomeric green fluorescent protein derived from the company’s mTFP1 protein. According to the company, mWasabi “is almost twice as bright as EGFP, and has a better excitation spectrum (much less UV excitation than EGFP or other Aequorea GFP variants, so will work quite a bit better for multiple-labeling applications), as well as likely performing just as well in fusion constructs as mTFP1.” 
Allele said the new protein “will be a very attractive choice” for researchers wanting to replace GFP in their assays with a “less-expensive” alternative. The company did not disclose the price of mWasabi. 

Thermo Fisher Scientific has introduced the Dharmacon Accell siRNA, a novel form of siRNA that is absorbed directly by cells without the use of conventional delivery methods such as transfection reagents, viruses, or electroporation.
According to the company, the siRNA can silence genes in all cell types tested to date when mixed with the optimized Accell delivery media and added to cultured cells.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more